Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been assigned a €95.10 ($113.21) target price by equities research analysts at J P Morgan Chase & Co in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Goldman Sachs Group, Inc. (The) set a €97.00 ($115.48) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Tuesday. Berenberg Bank set a €95.60 ($113.81) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Citigroup Inc. set a €92.00 ($109.52) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Deutsche Bank AG set a €84.00 ($100.00) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. Finally, Independent Research GmbH set a €88.00 ($104.76) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of €88.39 ($105.22).

Fresenius Medical Care AG & Co. KGaA (ETR FME) opened at 81.69 on Thursday. The stock has a market capitalization of €25.07 billion and a price-to-earnings ratio of 21.06. The company has a 50 day moving average of €79.20 and a 200 day moving average of €81.57. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €70.82 and a 12 month high of €89.07.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/16/fresenius-medical-care-ag-95-10-by-j-p-morgan-chase-co.html.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Stock Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related stocks with our FREE daily email newsletter.